Effect of Triticum Aestivum vs Placebo on Metabolic Profile Components and Insulin Sensitivity in Patients With Obesity
NCT06501248 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2024-07-15
Summary
Obesity is a metabolic disease which has been declared as the most prevalent chronic health problem in adults; according to the World Health Organization (WHO), it is defined as an increase in Body Mass Index (BMI) greater than or equal to 30 kg/m2.
In Mexico, according to data from the National Health and Nutrition Survey (ENSANUT) 2018-2019, the prevalence of overweight in adults is 39.1% (36.6% in women, 42.5% in men), of obesity is 36.1% (40.2% in women, 30.5% in men) and of abdominal adiposity 81.6% (88.4% in women and 72.1% in men), with a higher proportion found in the north of the country.
In 2010, it was estimated that obesity was the main cause of 3.4 million deaths, the main complications being cardiovascular disease, diabetes mellitus and various types of cancer.
The complications of obesity are very varied, mainly presenting changes in the metabolic profile, such as increased blood pressure and abdominal circumference, hypertriglyceridemia and hypercholesterolemia. Another of the main complications derived from obesity is insulin resistance, which is defined as a decreased biological response of peripheral tissues to a specific concentration of insulin with consequent compensatory hyperinsulinemia.
The treatment of obesity is based on lifestyle changes (diet and exercise), in addition, there are pharmacological and surgical treatments, however, they are not applicable to the entire population, so despite being a highly prevalent disease with major complications, current therapeutic options are insufficient.
Triticum aestivum, better known as wheat grass, is a very common fiber in the diet of the world population, including the Mexican population, in which multiple pre-clinical studies have been reported where the effect of triticum aestivum on the decrease of components of the metabolic profile, such as glycemia, cholesterol, triglycerides and weight, as well as an improvement in insulin sensitivity, has been evidenced; To date, no serious adverse effects related to its consumption have been described, and it can be considered as an effective therapeutic alternative for patients with obesity.
Conditions
- Obesity
- Drug Effect
- Insulin Sensitivity
Interventions
- DRUG
-
Triticum Aestivum
The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
- DRUG
-
Placebo (calcined magnesia)
The intervention period will be 120 days, searching for effects on insulin sensitivity and metabolic control.
Sponsors & Collaborators
-
Coordinación de Investigación en Salud, Mexico
lead OTHER_GOV
Principal Investigators
-
Sandra O Hernández González, PhD · Instituto Mexicano del Seguro Social, Unidad de Investigación Biomédica 02
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 30 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-07-14
- Primary Completion
- 2024-08-30
- Completion
- 2024-12-10
Countries
- Mexico
Study Locations
More Related Trials
-
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
NCT05110846 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Zenoctil in Reducing Body Weight
NCT01423617 ·Status: COMPLETED ·Phase: PHASE3
-
Benefit and Tolerability of IQP-AE-103 in Weight Loss
NCT03058367 ·Status: COMPLETED ·Phase: NA
-
Effects of Obex in Overweight and Obese Patients
NCT02145442 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
NCT06579092 ·Status: COMPLETED ·Phase: PHASE2
-
DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects
NCT04086797 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
NCT07142707 ·Status: RECRUITING ·Phase: PHASE1
-
Cinnamon and Withania on Weight Loss
NCT05210218 ·Status: COMPLETED ·Phase: NA
-
Innovative Functional Product for Overweight and Obesity
NCT07044167 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Dapagliflozin for Weight Loss
NCT03968224 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Functional Bioactive Supplement Effect in Lost Weight Treatment
NCT02024425 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption
NCT04926051 ·Status: COMPLETED ·Phase: PHASE1
-
Homeopathy for Overweight and Obesity in Mexican Adolescents
NCT03945396 ·Status: UNKNOWN ·Phase: PHASE2
-
Activity of Bioactive Natural Compounds as Potential Agonists of GLP1R
NCT06513715 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
B181 Metobes-III: Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)
NCT00302263 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Patients Being Treated With Anti-obesity Medication
NCT06790160 ·Status: RECRUITING
-
Evaluation of a Supplement for Weight Management in Obese and Overweight Individuals
NCT03812211 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Efficacy of the Composite WM Formula in Promoting GLP-1 Secretion
NCT07097987 ·Status: COMPLETED ·Phase: NA
-
Conjugated Linoleic Acid (1:1 Isomer Mixture) Intake in Overweight People
NCT01503047 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of ISOThrive on Bodyweight, Body Composition, Hunger/Satiety and Cardiac Risk Measures in Overweight Adults
NCT02501356 ·Status: COMPLETED ·Phase: NA
-
Personalized or Precision Medicine in the Dietary Approach to Obesity
NCT05420311 ·Status: UNKNOWN ·Phase: NA
-
Body Weight Response With Disulfiram in Humans
NCT05162001 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT07081958 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluation of SODB® in Metabolic Adaptations in Overweight Women
NCT02667691 ·Status: UNKNOWN ·Phase: NA
-
Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity
NCT04298203 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2